U.S. markets closed
  • S&P Futures

    3,454.00
    +4.75 (+0.14%)
     
  • Dow Futures

    28,299.00
    +31.00 (+0.11%)
     
  • Nasdaq Futures

    11,677.00
    +27.25 (+0.23%)
     
  • Russell 2000 Futures

    1,633.70
    +3.10 (+0.19%)
     
  • Crude Oil

    40.76
    +0.12 (+0.30%)
     
  • Gold

    1,908.80
    +4.20 (+0.22%)
     
  • Silver

    24.81
    +0.10 (+0.39%)
     
  • EUR/USD

    1.1805
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    0.8480
    +0.0320 (+3.92%)
     
  • Vix

    28.11
    -0.54 (-1.88%)
     
  • GBP/USD

    1.3071
    -0.0009 (-0.07%)
     
  • USD/JPY

    104.7140
    -0.1260 (-0.12%)
     
  • BTC-USD

    12,990.23
    +1,933.22 (+17.48%)
     
  • CMC Crypto 200

    261.95
    +5.85 (+2.28%)
     
  • FTSE 100

    5,785.65
    +9.15 (+0.16%)
     
  • Nikkei 225

    23,523.95
    +49.68 (+0.21%)
     

Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Announces Steven R. Martin to Join Board of Directors

·3 mins read

Ensysce: revolutionizing analgesia: tackling the biggest healthcare crises in the USA.

Ensysce Biosciences Inc., a clinical stage company launching new solutions for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, today announced the appointment of Steven R. Martin to its Board of Directors. Mr. Martin is Senior VP and Chief Financial Officer of Armata Pharmaceuticals, Inc. (NYSE: ARMP)​

Mr. Martin is an experienced senior executive and Chief Financial Officer with overall management and operational experience that has driven organizations to achieve their mission and goals. He has successfully served as CFO for five publicly-traded operating companies, with hands-on experience balancing opportunity and risk to develop highly effective finance organizations for new and growing public companies. Steve began his career as a CPA at Deloitte before transitioning into Controller, VP Finance and CFO roles. As a strategic leader and Chief Financial Officer, he has lead companies through successful public company exit transactions including while serving the dual role as Interim CEO and CFO. In addition to extensive SEC, M&A and IPO experience, Mr. Martin brings his broad experience in fund-raising, and other corporate administrative and governance matters to Ensysce.

Ensysce is undertaking the clinical development of 2 new classes of opioid pain medication with abuse and overdose protection, TAAP™ and MPAR™. In addition, Ensysce, and its newly formed subsidiary COVISTAT are exploring the use of an ingredient from its overdose protection technology, nafamostat, for the treatment of COVID-19. Nafamostat with its multimodal action and very favorable safety profile, has been reported to be one of the most potent inhibitors of SARS-CoV-2 viral entry into host cells. Ensysce and COVISTAT are launching a major trial in the coming weeks to make it a first line, low cost option for patients with coronaviral infections around the globe.

"Ensysce is leading the challenge of entering the opioid space when the political and regulatory climate is looking for new answers for analgesia, and as this pandemic is causing a rise in opioid related deaths. Ensysce believes in responsible analgesia for patients who require it, and believe TAAP™ and MPAR™ products will be able to save many lives." said Dr. Kirkpatrick, CEO of Ensysce Biosciences. "Opioids are necessary for many patients to lead normal lives including those with cancer pain, crippling arthritis and chronic back pain, and no effective alternative treatments are in sight. Ensysce is providing an option for both patients and prescribers that can reduce fear of addiction, stop abuse and stem overdose from these prescription products. Mr. Martin will provide the company with great leadership as we focus on responsible use of pain medication, and the need for solutions to the dilemma we now face in the midst of prescription drug abuse. Our TAAP™ oral prodrug technology and MPAR™ overdose protection, both unique to the industry, have already demonstrated exceptional clinical results. We look forward to rapidly progressing these agents through clinical development so the public can benefit from these safer pain medicines."

View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005128/en/

Contacts

Lynn Kirkpatrick, PhD
CEO
Ensysce Biosciences Inc.
www.ensysce.com
281-881-4140

Richard Wright
CBO
Ensysce Biosciences Inc
www.ensysce.com
281-881-4140